[Clinical characteristics and psychotropic therapy of depressive and anxious symptoms of patients with somatic diseases].
OBJECTIVE
To explore the characteristics of depressive and anxious symptoms and the drug therapy response of patients with somatic diseases.


METHODS
All the subjects were inpatients in a general hospital. The depressive and anxious symptoms met with the following conditions: hospital anxiety and depression scale (HAD) > 7 scores, Hamilton Depression Scale (HAMD) > 12, Hamilton Anxiety Scale (HAMA) > 10, Clinical Global Impression (CGI) > or = 3.


RESULTS
In patients 200, 195 received the therapy, and 5 discontinued. The severity of depressive symptom in descending order was tumor group, blood disease group, endocrine disease group, depressive group, cardiovascular disease group, renal disease group. The effects of Seroxat (serotonin selective reuptake inhibitor, SSRI): showed that the overall efficacy against depressive and anxious symptoms, measured with 50% reduction rate in endpoint scales scores, was 61.6% and 61.5% respectively.


CONCLUSIONS
Different characteristics of emotional symptoms existed among different somatic diseases. Seroxat is effective in treating emotional problems of patients with somatic diseases.
Wu
W
W
Department of Psychosomatic Medicine, Ganquan Hospital, Shanghai Tiedao University, Shanghai 200065.
Liu
M
M
Li
C
C
D000293:Adolescent; D000328:Adult; D001007:Anxiety / Q000188:drug therapy*; D003863:Depression / Q000188:drug therapy*; D005260:Female; D006769:Hospitals, General; D006801:Humans; D008297:Male; D008875:Middle Aged; D017374:Paroxetine / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D011602:Psychophysiologic Disorders / Q000188:drug therapy; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors